MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS

MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS

303415

MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS

MediciNova is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. “Over the past quarter, we have continued to advance our novel anti-inflammatory candidates across all stages of development,” Yuichi Iwaki, MD, PhD, MediciNova’s president and CEO, said in a press release regarding the…

You must be logged in to read/download the full post.